Biosimilars: The Balance between Affordable Drugs and New Research

more+
less-

Generic drugs play an important role in reducing health care costs. Historically, Congress has attempted to maintain a balance between providing affordable medicine in the form of generics, while protecting the income of pharmaceutical companies who spend millions of dollars and years of research to launch a new drug. If too much emphasis is placed on producing generic drugs, investors lack incentives to fund new research. In short, there will be no drug for the generic to imitate. In the field of biologics, i.e. biological based medicine, the United States was without a legal option to produce generics. Recently, the President signed into law a provision to allow biosimilars.

LOADING PDF: If there are any problems, click here to download the file.


DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Kevin Rider | Attorney Advertising

Written by:

more+
less-

Kevin Rider on:

JD Supra Readers' Choice 2016 Awards
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:

Sign up to create your digest using LinkedIn*

*By using the service, you signify your acceptance of JD Supra's Privacy Policy.

Already signed up? Log in here

*With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name. Or, sign up using your email address.
×
Loading...
×
×